Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Sebastian Grosicki(Medical University of Silesia), Maryana Simonova(Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine), Ivan Špıčka(Charles University), Luděk Pour(University Hospital Brno), Iryrna Kriachok(National Cancer Institute), Maria Gavriatopoulou(National and Kapodistrian University of Athens), Halyna Pylypenko, Holger W. Auner(Imperial College London), Xavier Leleu(Inserm), Vadim Doronin(City Clinical Hospital), Ganna Usenko, Nizar J. Bahlis(University of Calgary), Roman Hájek(University of Ostrava), Reuben Benjamin(King's College London), Tuphan Kanti Dolai(Nil Ratan Sircar Medical College and Hospital), Dinesh Kumar Sinha(Indira Gandhi Institute of Medical Sciences), Christopher P. Venner(University of Alberta), Mamta Garg(University Hospitals of Leicester NHS Trust), Mercedes Gironella(Vall d'Hebron Hospital Universitari), Artur Jurczyszyn(Jagiellonian University), Paweł Robak(Copernicus Memorial Hospital), Mónica Galli(Ospedale Papa Giovanni XXIII), Craig T. Wallington‐Beddoe(Flinders University), Atanas Radinoff(University Hospital St. Ivan Rilski), Galina Salogub(Federal Almazov North-West Medical Research Centre), Don A. Stevens(Norton Healthcare), Supratik Basu(University of Wolverhampton), Anna Marina Liberati(University of Perugia), Hang Quach(The University of Melbourne), Vesselina Goranova‐Marinova(Medical University Plovdiv), Jelena Bila, Eirini Katodritou(Theageneio General Hospital), Hanna Oliynyk, Sybiryna Korenkova(Kyiv City Clinical Oncology Center), Jeevan Kumar(Tata Medical Center), Sundar Jagannath(Icahn School of Medicine at Mount Sinai), Philippe Moreau, Moshe Levy(Baylor University Medical Center), Darrell White(Dalhousie University), Moshe E. Gatt(Hadassah Medical Center), Thierry Façon(Centre Hospitalier Universitaire de Lille), María‐Victoria Mateos(Complejo Hospitalario de Salamanca), Michèle Cavo(Istituto di Ematologia di Bologna), Donna Reece(University Health Network), Larry D. Anderson(The University of Texas Southwestern Medical Center), Jean-Richard Saint-Martin(Karyopharm Therapeutics (United States)), Jacqueline Jeha(Karyopharm Therapeutics (United States)), Anita Joshi(Karyopharm Therapeutics (United States)), Yi Chai(Karyopharm Therapeutics (United States)), Lingling Li(Karyopharm Therapeutics (United States)), Vishnuvardhan Peddagali(Karyopharm Therapeutics (United States)), Melina Arazy(Karyopharm Therapeutics (United States)), Jatin J. Shah(Karyopharm Therapeutics (United States)), Sharon Shacham(Karyopharm Therapeutics (United States)), Michael Kauffman(Karyopharm Therapeutics (United States)), Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Paul G. Richardson(Dana-Farber Cancer Institute), Sosana Delimpasi(Evangelismos Hospital)
Cited by 321Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis